BNR vs ACMR vs EXAS vs ICHR vs MKSI

For growth investors, Exact Sciences Corporation (EXAS) is the stronger pick with 17.

7% revenue growth year-over-year, versus -4. 0% for Burning Rock Biotech Limited (BNR). ACM Research, Inc. (ACMR) offers the better valuation at 43. 7x trailing P/E (30. 8x forward), making it the more compelling value choice. Analysts rate Burning Rock Biotech Limited (BNR) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACM Research, Inc.

(ACMR) is the cheapest at 43. 7x versus MKS Inc. at 71. 7x. On forward P/E, MKS Inc. is actually cheaper at 27. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, ACM Research, Inc.

(ACMR) delivered a total return of +167. 3%, compared to -93. 6% for Burning Rock Biotech Limited (BNR). Over 10 years, the gap is even starker: ACMR returned +31. 0% versus BNR's -93. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

05β versus Ichor Holdings, Ltd. 's 3. 78β — meaning ICHR is approximately 7080% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Burning Rock Biotech Limited (BNR) carries a lower debt/equity ratio of 9% versus 173% for MKS Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Exact Sciences Corporation (EXAS) is pulling ahead at 17.

7% versus -4. 0% for Burning Rock Biotech Limited (BNR). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to -140. 6% for Ichor Holdings, Ltd.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACM Research, Inc.

(ACMR) is the more profitable company, earning 10. 4% net margin versus -67. 2% for Burning Rock Biotech Limited — meaning it keeps 10. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MKSI leads at 14. 4% versus -69. 3% for BNR. At the gross margin level — before operating expenses — BNR leads at 70. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, MKS Inc.

(MKSI) trades at 27. 3x forward P/E versus 582. 8x for Exact Sciences Corporation — 555. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACMR: 25. 3% to $75. 00.

In this comparison, MKSI (0.

3% yield), ACMR (0. 2% yield) pay a dividend. BNR, EXAS, ICHR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), +1669% 10Y return). ACM Research, Inc. (ACMR) carries a higher beta of 3. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, ACMR: +31. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BNR (Healthcare) and ACMR (Technology) and EXAS (Healthcare) and ICHR (Technology) and MKSI (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BNR is a small-cap quality compounder stock; ACMR is a small-cap high-growth stock; EXAS is a mid-cap high-growth stock; ICHR is a small-cap quality compounder stock; MKSI is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.